De novo coding variants in the AGO1 gene cause a neurodevelopmental disorder with intellectual disability

Audrey Schalk, Margot A. Cousin, Nikita R. Dsouza, Thomas D. Challman, Karen E. Wain, Zoe Powis, Kelly Minks, Aurélien Trimouille, Eulalie Lasseaux, Didier Lacombe, Chloé Angelini, Vincent Michaud, Julien Van-Gils, Nino Spataro, Anna Ruiz, Elizabeth Gabau, Elliot Stolerman, Camerun Washington, Ray Louie, Brendan C. LanpherJennifer L. Kemppainen, Micheil Innes, Frank Kooy, Marije Meuwissen, Alice Goldenberg, Francois Lecoquierre, Gabriella Vera, Karin E.M. Diderich, Beth Sheidley, Christelle Moufawad El Achkar, Meredith Park, Fadi F. Hamdan, Jacques L. Michaud, Ann J. Lewis, Christiane Zweier, André Reis, Matias Wagner, Heike Weigand, Hubert Journel, Boris Keren, Sandrine Passemard, Cyril Mignot, Koen Van Gassen, Eva H. Brilstra, Gina Itzikowitz, Emily O'Heir, Jake Allen, Kirsten A. Donald, Bruce Richard Korf, Tammi Skelton, Michelle Thompson, Nathaniel H. Robin, Natasha L. Rudy, William B. Dobyns, Kimberly Foss, Yuri Alexander Zarate, Katherine A. Bosanko, Yves Alembik, Benjamin Durand, Frederic Tran Mau-Them, Emmanuelle Ranza, Xavier Blanc, Stylianos E. Antonarakis, Kirsty McWalter, Erin Torti, Francisca Millan, Amy Dameron, Mari Tokita, Michael T. Zimmermann, Eric W Klee, Amelie Piton, Benedicte Gerard

Research output: Contribution to journalArticlepeer-review

9 Scopus citations

Abstract

Background High-impact pathogenic variants in more than a thousand genes are involved in Mendelian forms of neurodevelopmental disorders (NDD). Methods This study describes the molecular and clinical characterisation of 28 probands with NDD harbouring heterozygous AGO1 coding variants, occurring de novo for all those whose transmission could have been verified (26/28). Results A total of 15 unique variants leading to amino acid changes or deletions were identified: 12 missense variants, two in-frame deletions of one codon, and one canonical splice variant leading to a deletion of two amino acid residues. Recurrently identified variants were present in several unrelated individuals: p.(Phe180del), p.(Leu190Pro), p.(Leu190Arg), p.(Gly199Ser), p.(Val254Ile) and p.(Glu376del). AGO1 encodes the Argonaute 1 protein, which functions in gene-silencing pathways mediated by small non-coding RNAs. Three-dimensional protein structure predictions suggest that these variants might alter the flexibility of the AGO1 linker domains, which likely would impair its function in mRNA processing. Affected individuals present with intellectual disability of varying severity, as well as speech and motor delay, autistic behaviour and additional behavioural manifestations.

Original languageEnglish (US)
Pages (from-to)965-975
Number of pages11
JournalJournal of medical genetics
Volume59
Issue number10
DOIs
StatePublished - 2022

Bibliographical note

Funding Information:
Research reported in this publication was supported by the National Institute Of Mental Health of the National Institutes of Health under Award Number U01MH119689. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. We also thank the CREGEMES for its financial support.

Publisher Copyright:
© Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and permissions. Published by BMJ.

Keywords

  • genetics
  • medical
  • microRNA
  • missense
  • mutation
  • nervous system diseases
  • Humans
  • Argonaute Proteins/genetics
  • Intellectual Disability/genetics
  • Heterozygote
  • Amino Acids/genetics
  • RNA, Messenger
  • Neurodevelopmental Disorders/genetics

PubMed: MeSH publication types

  • Journal Article
  • Research Support, N.I.H., Extramural

Fingerprint

Dive into the research topics of 'De novo coding variants in the AGO1 gene cause a neurodevelopmental disorder with intellectual disability'. Together they form a unique fingerprint.

Cite this